News Takeda Pharmaceutical Company Limited

Stocks

4502

JP3463000004

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:30:00 2026-07-15 EDT			5-day change	1st Jan Change
5,288.00 ^JPY	-0.73%		-2.99%	+9.37%

10:23pm	Taiwan's Bora Pharmaceuticals in potential $2.5 billion collaboration with Insilico Medicine	RE
07-13	Takeda, Indonesian Government Launch Program to Build National Plasma Ecosystem	MT

All News

Mentions Relevance

07-13	Takeda, Indonesian Government Launch Program to Build National Plasma Ecosystem	MT
07-12	Takeda Pharmaceutical Company Limited and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products	CI
07-12	Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products	BU
07-09	Takeda Pharmaceutical : Filing of Corporate Governance Report to the Tokyo Stock Exchange	PU
07-08	Takeda Pharmaceutical Completes Share Issuance, Disposal Under Incentive Plan	MT
07-08	Takeda Pharmaceutical : Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees	PU
07-02	Takeda, Insilico Sign AI-Driven Drug Discovery Pact	MT
07-01	Insilico Medicine Strikes Drug Discovery Deal With Japan's Takeda Pharmaceutical	MT
06-24	Takeda Pharmaceutical Company Limited Announces Dividend Payment	CI
06-24	Takeda Pharmaceutical Company Limited Announces Management and Committee Changes	CI
06-24	Takeda Pharmaceutical Company Limited Announces Appointment of Julie Kim as Chief Executive Officer	CI
06-24	Takeda Pharmaceutical : Integrated Report (AIR 2026 EN)	PU
06-24	Takeda Pharmaceutical Appoints Julie Kim as Chief Executive	MT
06-24	Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO	BU
06-23	Takeda Canada Says Zasocitinib Shows Superiority to Deucravacitinib in Phase 3 Psoriasis Study	MT
06-15	Takeda Pharmaceutical Company Limited Presents Additional Results from Two Pivotal Studies Showing Oveporexton Improves Daily Function, Cognition, and Nighttime Sleep for People with Narcolepsy Type 1	CI
06-15	New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1	BU
06-11	Takeda Pharmaceutical's Psoriasis Treatment Beats Competitor in Trial	MT
06-11	Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations	BU
06-11	Takeda Announces Positive Topline Results for Phase 3 Study Comparing Zasocitinib to Deucravacitinib in Adults with Moderate-To-Severe Plaque Psoriasis	CI
06-10	Takeda Pharmaceutical to Issue 17 Million Shares Under Employee Incentive Plan	MT
06-09	Takeda's Application for ENTYVIO IV Accepted by FDA in Pediatric Ulcerative Colitis and Crohn's Disease	MT
06-09	U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease	BU
06-09	Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan	PU
06-05	Takeda Books $2.5 Billion Provision Related to Amitiza Antitrust Litigation	DJ